Cytokinetics Inc (CYTK) stock
CYTKNasdaqPharmaceutical PreparationsFiscal year ends December 31
$56.13−0.03 (-0.05%)
Close on Nov 13, 2026Market cap $7.80BP/E –Yield –
Cytokinetics EPS
Diluted earnings per share is net income divided by the share count including options and convertible securities.
Cytokinetics's EPS for the twelve months ending Sep 30, 2018 was -$2.22. For fiscal 2025 it was -$6.54. The highest annual figure on record is $2.52 in fiscal 2009.
Annual eps
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$6.54 | – |
| FY2024 | Dec 31, 2024 | -$5.26 | – |
| FY2023 | Dec 31, 2023 | -$5.45 | – |
| FY2022 | Dec 31, 2022 | -$4.33 | – |
| FY2021 | Dec 31, 2021 | -$2.80 | – |
| FY2020 | Dec 31, 2020 | -$1.97 | – |
| FY2019 | Dec 31, 2019 | -$2.11 | – |
| FY2018 | Dec 31, 2018 | -$1.95 | – |
| FY2017 | Dec 31, 2017 | -$2.59 | -764.1% |
| FY2016 | Dec 31, 2016 | $0.39 | – |
| FY2015 | Dec 31, 2015 | -$0.97 | – |
| FY2014 | Dec 31, 2014 | -$0.41 | – |
| FY2013 | Dec 31, 2013 | -$1.24 | – |
| FY2012 | Dec 31, 2012 | -$2.30 | – |
| FY2011 | Dec 31, 2011 | -$4.30 | – |
| FY2010 | Dec 31, 2010 | -$4.62 | -283.3% |
| FY2009 | Dec 31, 2009 | $2.52 | – |
Quarterly eps
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q3 FY2026 | Sep 30, 2026 | -$1.37 | – |
| Q2 FY2026 | Jun 30, 2026 | -$1.50 | – |
| Q1 FY2026 | Mar 31, 2026 | -$1.67 | – |
| Q3 FY2025 | Sep 30, 2025 | -$2.55 | – |
| Q2 FY2025 | Jun 30, 2025 | -$1.12 | – |
| Q1 FY2025 | Mar 31, 2025 | -$1.36 | – |
| Q3 FY2024 | Sep 30, 2024 | -$1.36 | – |
| Q2 FY2024 | Jun 30, 2024 | -$1.31 | – |
| Q1 FY2024 | Mar 31, 2024 | -$1.33 | – |
| Q3 FY2023 | Sep 30, 2023 | -$1.35 | – |
| Q2 FY2023 | Jun 30, 2023 | -$1.34 | – |
| Q1 FY2023 | Mar 31, 2023 | -$1.38 | – |
| Q3 FY2022 | Sep 30, 2022 | -$1.52 | – |
| Q2 FY2022 | Jun 30, 2022 | -$0.23 | – |
| Q1 FY2022 | Mar 31, 2022 | -$1.05 | – |
| Q3 FY2021 | Sep 30, 2021 | -$0.95 | – |
| Q2 FY2021 | Jun 30, 2021 | -$0.86 | – |
| Q1 FY2021 | Mar 31, 2021 | -$0.66 | – |
| Q3 FY2020 | Sep 30, 2020 | -$0.05 | – |
| Q2 FY2020 | Jun 30, 2020 | -$0.68 | – |
| Q1 FY2020 | Mar 31, 2020 | -$0.66 | – |
| Q3 FY2019 | Sep 30, 2019 | -$0.50 | – |
| Q2 FY2019 | Jun 30, 2019 | -$0.56 | – |
| Q1 FY2019 | Mar 31, 2019 | -$0.54 | – |
| Q3 FY2018 | Sep 30, 2018 | -$0.40 | – |
| Q2 FY2018 | Jun 30, 2018 | -$0.51 | – |
| Q1 FY2018 | Mar 31, 2018 | -$0.56 | – |
| Q4 FY2017 | Dec 31, 2017 | -$0.75 | -568.8% |
| Q3 FY2017 | Sep 30, 2017 | -$0.60 | – |
| Q2 FY2017 | Jun 30, 2017 | -$0.60 | – |
| Q1 FY2017 | Mar 31, 2017 | -$0.62 | – |
| Q4 FY2016 | Dec 31, 2016 | $0.16 | – |
- Revenue
- Gross Profit
- Operating Income
- Net Income
- EBITDA
- Free Cash Flow
- Operating Cash Flow
- R&D Expenses
- Gross Margin
- Operating Margin
- Profit Margin
- Total Debt
- Cash
- Total Assets
- Shares Outstanding
- Market Cap
- Enterprise Value
- PE Ratio
- Price to Sales Ratio
- Price to Book Ratio
- EV/EBITDA
- Price to Free Cash Flow
- All statistics
See a number that looks wrong?